Neuraxpharm enhances ADHD treatment options in Europe with launches of Tuzulby® chewable tablets and Paxneury®

Launches of Tuzulby® methylphenidate prolonged-release chewable tablets and Paxneury® guanfacine prolonged-release tablets, also in 5mg, 6mg, and 7mg strengths

Two differentiated treatments exemplify Neuraxpharm’s commitment to bringing a choice of solutions to ADHD patients across Europe

Barcelona, Spain and Düsseldorf, Germany – 12 January 2026 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, today announces the launches in Europe of Tuzulby® (methylphenidate hydrochloride) prolonged-release chewable tablets and Paxneury® (guanfacine) prolonged-release tablets, two differentiated treatments designed to meet the diverse needs of children and adolescents living with attention deficit and hyperactivity disorder (ADHD).

Tuzulby® prolonged-release chewable tablets, developed by Tris Pharma and available since December 2025 in Germany, the UK and the Nordic countries, is the first and only once-daily, prolonged-release, chewable methylphenidate tablet for children and adolescents with ADHD in Europe. Indicated for those aged 6-17 years, it is part of a holistic treatment programme for ADHD when remedial measures alone prove insufficient1. It enables flexible, individualised dosing according to the treatment needs and responses of the patient with a convenient chewable format to support treatment adherence1, 2. Further launches across Europe are planned in the coming months.

Paxneury®, a second-line treatment in ADHD management3, launched in September in multiple European countries, is the only prolonged-release guanfacine formulation in Europe to offer a wider spectrum of strengths, with higher doses of 5mg, 6mg, and 7mg launched. Licensed for the treatment of ADHD in children and adolescents aged 6–17 years for whom stimulants are not suitable, not tolerated or are shown to be ineffective4, it allows for individualised dosing according to the patient’s response and tolerability and is the first generic prolonged-release guanfacine to reach the European market. It was developed by HealthTech, Neuraxpharm’s R&D center specializing in delivering innovative solutions in the CNS field, like this value added product.

With the introduction of these two differentiated medicines, Neuraxpharm reinforces its commitment to advancing ADHD care in Europe through its comprehensive portfolio offering added-value support for patients, families and healthcare providers.

Dr. Jörg Thomas Dierks, CEO of Neuraxpharm, commented: “With these launches, we are proud to deliver two differentiated solutions that expand treatment choice and flexibility for prescribing doctors. These product offerings reflect our ongoing strategy to make a range of innovative CNS therapies widely available across Europe.”

ADHD is a neurodevelopmental disorder defined by impaired levels of inattention, disorganization and/or hyperactivity-impulsivity5. In Europe, approximately 5% of children and adolescents are affected by this condition6.

References

1.      Tuzulby prolonged-release chewable tablets SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/tuzulby-epar-product-information_en.pdf (Accessed: November 2025).

2.      World Health Organization. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization; 2003. ISBN: 92-4-154599-2.

3.      Coghill D, Banaschewski T, Cortese S et al. The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). Eur Child Adolesc Psychiatry. 2023 Aug;32(8):1337-1361.

4.      Paxneury prolonged-release tablets SmPC. Available at: https://www.ema.europa.eu/en/documents/product-information/paxneury-epar-product-information_en.pdf (Accessed: November 2025).

5.      American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.).

6.      Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007 Jun;164(6):942-8.